Deans' stroke musings: Low circulating acute brain-derived neurotrophic factor levels are associated with poor long-term functional outcome after ischemic stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, July 14, 2016

Low circulating acute brain-derived neurotrophic factor levels are associated with poor long-term functional outcome after ischemic stroke

So, What the hell is the solution? What do we need to do to increase BDNF levels? WHO IS GOING TO ANSWER THAT SIMPLE QUESTION AND ACTUALLY HELP SURVIVORS?
http://www.mdlinx.com/neurology/medical-news-article/2016/07/13/brain-derived-neurotrophic-factor-pathogenesis-risk-factors-serum-stroke/6735204/?category=top-read&page_id=1

Stanne TM, et al. – The clinicians performed this work to examine whether circulating concentrations of brain–derived neurotrophic factor (BDNF) are altered in the acute phase of ischemic stroke and whether they are connected with short– or long–term functional outcome. This study suggests that in the acute phase of ischemic stroke, circulating concentrations of BDNF protein are brought down and low levels are connected with poor long–term functional outcome. They added that to confirm these affiliations and to determine the predictive value of BDNF in stroke outcomes further studies are essential.

Methods

In the Sahlgrenska Academy Study on Ischemic Stroke, serum concentrations of BDNF were measured.
To pursue this research the primary results were adjusted Rankin Scale (mRS) good (mRS score of 0–2) versus poor (mRS score of 3–6) at 3 months and 2 years after stroke, and good (mRS score of 0–2) versus poor (mRS score of 3–5) at 7 years after stroke.

Results

Researchers found that acute concentrations of BDNF were significantly lower in ischemic stroke cases (n=491) compared with controls (n=513).
With 3-month outcome, BDNF concentrations were not significantly associated.
The present study showed that patients with BDNF in the lowest tertile had an expanded risk of experiencing a poor outcome both at 2-year and 7-year follow-up, and these affiliations were independent of vascular risk factors and stroke severity (odds ratio, 2.6; confidence intervals, 1.4–4.9; P=0.002 and odds ratio, 2.1; confidence intervals, 1.1–3.9; P=0.028, respectively).

Go to PubMed Go to Abstract Print Article Summary Cat 2 CME Report